Moderna and Cenra Healthcare Enter Joint Agreement to Promote mRNA Vaccines in Taiwan

CAMBRIDGE, MA and TAIPEI, TAIWAN - Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare have entered into a joint agreement to co-promote Moderna's mRNA respiratory vaccine portfolio in Taiwan, including the COVID-19 vaccine Spikevax®. The collaboration aims to enhance the distribution and educational outreach of these vaccines across the region.

Moderna will manage the manufacturing and distribution aspects, while Cenra Healthcare will focus on promotion and medical education activities. The agreement lasts until July 31, 2027; financial terms remain undisclosed.

Joyce Lee, General Manager of Moderna in Taiwan, expressed confidence in Cenra Healthcare's strong market presence and expertise in infectious diseases to support broader access to the vaccines. Lucas Lin, General Manager of Cenra Healthcare, emphasized the importance of this partnership in reinforcing Taiwan's public health initiatives.